5α-Reductases in Human Breast Carcinoma: Possible Modulator of in Situ Androgenic Actions1
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The expression of 5alpha-reductase types 1 and 2 was examined in human breast carcinoma using immunohistochemistry and RT-PCR. Immunoreactivity for 5alpha-reductase isozymes was also correlated with various clinicopathological parameters to examine possible local regulatory mechanisms of sex steroids, including progesterone and androgens, in human breast carcinoma tissues. Immunoreactivity for 5alpha-reductase type 1 was detected in the cytoplasm and possibly in the nuclear membrane of tumor cells in 35 of 60 invasive ductal carcinomas (58%), and type 2 signal was detected in 9 of these 60 cases (15%). The results from RT-PCR (n = 8) were consistent with those from immunohistochemistry. A significant positive correlation was detected between 5alpha-reductase type 1 immunoreactivity and androgen and progesterone receptor A or B labeling indexes, and immunoreactivities of 5alpha-reductase type 2, 17beta-hydroxysteroid dehydrogenase type 5, or 3beta-hydroxysteroid dehydrogenase, which recognizes both types I and II. An inverse correlation was detected between 5alpha-reductase type 1 immunoreactivity and tumor size, histological grade, or Ki-67 labeling index. 5alpha-Reductase type 2 immunoreactivity was significantly correlated with 17beta-hydroxysteroid dehydrogenase type 5 immunoreactivity, but not with other parameters. This study suggests that 5alpha-reductase type 1 is mainly expressed in human breast carcinoma, which may play an important role in the in situ production and actions of the potent androgen, 5alpha-dihydrotestosterone, including inhibition of cancer cell proliferation, in hormone-dependent human breast carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Schwab, U., Lemke, H., & Stein, H. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910310104 · Cited by 2,788
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105 · cited 3×
“5a-Reductases catalyze the conversion of testosterone to the bioactive and potent androgen, 5a-dihydrotestosterone (DHT), and metabolize progesterone to 5a-dihydroprogesterone (5aDHP) (11).”
BackgroundResultTissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727 · cited 5×
“The characterization of these three antibodies was confirmed by Western blotting (12, 19), and use of antibodies for 5a-reductase type 2 (20) and 17bHSD type 5 (19) on immunohistochemistry has been previously reported.”
BackgroundMethodInfluentialDeletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism
Andersson, S., Berman, D. M., Jenkins, E. P., & Russell, D. W. (1991) · Nature · doi:10.1038/354159a0 · Cited by 643
Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle
ABRAHAM, G. E. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-39-2-340 · Cited by 436
Molecular genetics of steroid 5 alpha-reductase 2 deficiency
Thigpen, A. E., Davis, D. L., Milatovich, A., Mendonca, B. B., Imperato-McGinley, J., Griffin, J. E., Francke, U., Wilson, J. D., & Russell, D. W. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115954 · Cited by 422
Endocrine treatment of breast cancer in women
SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-221 · Cited by 399 · cited 2×
“Administration of androgens has been reported to result in the regression of some cases of breast carcinoma, but also to cause androgenic side-effects (5).”
BackgroundPoulin, R., Baker, D., & Labrie, F. (1988) · Breast Cancer Research and Treatment · doi:10.1007/bf01805942 · Cited by 172
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Sasano, H., Frost, A. R., Saitoh, R., Harada, N., Poutanen, M., Vihko, R., Bulun, S. E., Silverberg, S. G., & Nagura, H. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.11.8923858 · Cited by 167
Self-citationLabrie, F., Simard, J., Luu-The, V., Pelletier, G., Bélanger, A., Lachance, Y., Zhao, H. F., Labrie, C., Breton, N., de Launoit, Y., et al. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90368-s · Cited by 88 · cited 1×
“It was raised in rabbits against purified human placental 3bHSD (21), and the immunoreactivity has also been demonstrated in human adrenals (22), indicating that this antibody detects both 3bHSD types I and II (23).”
BackgroundPelletier, G., Luu-The, V., Tětu, B., & Labrie, F. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904700602 · Cited by 88
Factors affecting sex hormone levels in postmenopausal women.
Vermeulen, A., & Verdonck, L. (1979) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(79)90027-x · Cited by 61
Mistry, P., Griffiths, K., & Maynard, P. V. (1986) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(86)90372-9 · Cited by 34 · cited 1×
“Physiological concentrations of potent androgens such as DHT were very low in normal woman (32–34) and in breast cancer patients (35).”
BackgroundPerel, E., Daniilescu, D., Kharlip, L., Blackstein, M. E., & Killinger, D. W. (1985) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(85)90023-1 · Cited by 17 · cited 2×
“Activity of 5a-reductase has previously been demonstrated in various human breast carcinoma cell lines (15, 31), and Wiebe et al.”
Background
Cited by
Selective Estrogen Receptor Modulators
Frasor, J., Stossi, F., Danes, J. M., Komm, B., Lyttle, C. R., & Katzenellenbogen, B. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3326 · Cited by 395
Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?
Hickey, T. E., Robinson, J. L. L., Carroll, J. S., & Tilley, W. D. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1107 · Cited by 289
Sex steroid-producing enzymes in human breast cancer
Suzuki, T., Miki, Y., Nakamura, Y., Moriya, T., Ito, K., Ohuchi, N., & Sasano, H. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00834 · Cited by 182
“4F), while that of 5a-reductase type 2 was detected in only 15% of breast carcinomas (Suzuki et al. 2001a), suggesting that 5a-reductase type 1 may mainly determine 5a-reductase activity in breast carcinoma tissues.”
BackgroundInfluentialSelf-citationSteroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma
Utsunomiya, H., Ito, K., Suzuki, T., Kitamura, T., Kaneko, C., Nakata, T., Niikura, H., Okamura, K., Yaegashi, N., & Sasano, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0040 · Cited by 85
“Recent studies demonstrated that the bioactive androgen 5 -dihydrotestosterone is locally produced from dehydroepiandrosterone (36, 37) in human breast cancer tissues.”
BackgroundSelf-citation17β-hydroxysteroid dehydrogenases in human endometrium and its disorders
Ito, K., Utsunomiya, H., Suzuki, T., Saitou, S., Akahira, J.-I., Okamura, K., Yaegashi, N., & Sasano, H. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.11.038 · Cited by 54
Self-citation
Metadata
- Authors
- Suzuki, T., Darnel, A. D., Akahira, J.-I., Ariga, N., Ogawa, S., Kaneko, C., Takeyama, J., Moriya, T., & Sasano, H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-05
- Volume
- 86
- Issue
- 5
- Pages
- 2250-2257
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1969873699
- Cited by
- 72
- References
- 14
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.